SCHEMBL2291665

SCHEMBL2291665

Cc1cc(C(=O)Nc2ccccc2C(=O)O)ccc1Oc1ccccc1F

nearest known ligand 0.65

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
CHEK1 O14757 1/20 0.60
PIM1 P11309 1/20 0.60
MAPK8 P45983 1/20 0.60
CLK4 Q9HAZ1 1/20 0.60
MEN1 O00255 2/20 0.57
KMT2A Q03164 2/20 0.57
NPC1 O15118 1/20 0.57
ALDH1A1 P00352 1/20 0.57
HTT P42858 1/20 0.57
RAB9A P51151 1/20 0.57
KCNH2 Q12809 1/20 0.57
CTDSP1 Q9GZU7 1/20 0.54
NOD2 Q9HC29 1/20 0.54
P2RY14 Q15391 1/20 0.53
PKM P14618 1/20 0.53
POLB P06746 1/20 0.51
MAPK1 P28482 1/20 0.51
NPSR1 Q6W5P4 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2291837 0.93 CHEK1 (0.58) CHEK1PIM1MAPK8CLK4MEN1
SCHEMBL2292834 0.86 CHEK1 (0.65) CHEK1PIM1MAPK8CLK4MEN1
SCHEMBL2294360 0.84 CHEK1 (0.57) CHEK1PIM1MAPK8CLK4MEN1
SCHEMBL2292482 0.82 TDP1 (0.62) MEN1KMT2ANPC1RAB9A
SCHEMBL28275272 0.81 LMNA (0.51) HTTRAB9AP2RY14MAPK1
SCHEMBL2290704 0.78 SMN1; SMN2 (0.57) CHEK1PIM1MAPK8CLK4MEN1
SCHEMBL2292384 0.77 MEN1 (0.63) CHEK1PIM1MAPK8CLK4MEN1
SCHEMBL28869415 0.76 NOTUM (0.47) KMT2ANPC1ALDH1A1HTTRAB9A
SCHEMBL14227315 0.76 MEN1 (0.66) CHEK1PIM1MAPK8CLK4MEN1
SCHEMBL2291520 0.76 SMN1; SMN2 (0.57) MEN1KMT2ANPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7989657-B2 Anthranilic acid derivatives HOFFMANN-LA ROCHE INC. (US) 2011-08-02 US claimed
US-20090247637-A1 Novel Anthranilic Acid Derivatives DEHMLOW HENRIETTA 2009-10-01 US claimed
JP-2008546661-A 2008-12-25 JP claimed
EP-1896396-A1 ANTHRANILIC ACID DERIVATIVES F.HOFFMANN-LA ROCHE AG (CH) 2008-03-12 EP claimed
WO-2006134040-A1 ANTHRANILIC ACID DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2006-12-21 WO claimed
US-20060281810-A1 Novel anthranilic acid derivatives HOFFMANN-LA ROCHE INC. 2006-12-14 US claimed
US-7989657-B2 Anthranilic acid derivatives HOFFMANN-LA ROCHE INC. (US) 2011-08-02 US disclosed
US-20090247637-A1 Novel Anthranilic Acid Derivatives DEHMLOW HENRIETTA 2009-10-01 US disclosed
EP-1896396-A1 ANTHRANILIC ACID DERIVATIVES F.HOFFMANN-LA ROCHE AG (CH) 2008-03-12 EP disclosed
WO-2006134040-A1 ANTHRANILIC ACID DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2006-12-21 WO disclosed
US-20060281810-A1 Novel anthranilic acid derivatives HOFFMANN-LA ROCHE INC. 2006-12-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060281810-A1 Novel anthranilic acid derivatives GPR84, HCAR1, GPR88 CHEK1 4126/4885PIM1 4409/4885MAPK8 1419/4885
US-20090247637-A1 Novel Anthranilic Acid Derivatives GPR84, GPR88, HCAR1 CHEK1 4268/4885PIM1 4236/4885MAPK8 1347/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.